@article {HERCEG2913, author = {MEGAN E. HERCEG and ATHANASIOS C. TSIATIS and JENNIFER L. HALPERN and GINGER E. HOLT and HERBERT S. SCHWARTZ and VICKI L. KEEDY and JUSTIN M.M. CATES}, title = {Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma}, volume = {29}, number = {8}, pages = {2913--2917}, year = {2009}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Cyclooxygenase 2 (COX2) expression is up-regulated and associated with adverse prognosis in select types of carcinoma. Although not extensively studied in skeletal or soft tissue sarcoma, expression of COX2 has been described in a variable number of gynecological and non-gynecological leiomyosarcomas. In this study, the prevalence and prognostic implications of COX2 expression in leiomyosarcoma were evaluated further. Materials and Methods: Immunohistochemical stains for COX2 were performed on 33 samples of soft tissue leiomyosarcoma and tested for their association with clinicopathological parameters and patient outcome. Results: COX2 staining was limited to tumor cells surrounding areas of tumor necrosis in 6 cases. There were no statistically significant correlations with the clinicopathological parameters studied, including local recurrence, distant metastasis, or disease-specific death. Conclusion: The low frequency, restricted distribution and absence of prognostic implications of COX2 expression soft tissue leiomyosarcoma suggest that this enzyme may not be a useful pharmacological target in this clinical setting.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/29/8/2913}, eprint = {https://ar.iiarjournals.org/content/29/8/2913.full.pdf}, journal = {Anticancer Research} }